If you're the founder or CFO of a science-based startup, you need to understand your financing options. You’re looking for a law firm that can introduce you to venture capitalists and other funding sources, and at the same time, you want legal counsel that understands your company’s potential in order to strike a deal that acknowledges the value you’re creating and protects your interests.
At Faber, we’ve represented 2,000+ clients in life science, healthcare IT, medical devices and engineering technology. We often act as corporate counsel and provide legal guidance to management and boards of directors alike on the full range of private financing options.
We have strong relationships with the investor groups that focus on these verticals and have advised many of them on their own transactions.
Based on your circumstances, we’ll advise you on the optimal source of financing, including:
We have been actively involved in preparing model documents published by the National Venture Capital Association. But we also recognize that successful deals are about more than contract terms. Faber’s sector focus prepares us to understand your opportunities and challenges.
Tasca Therapeutics launches with $52 million in Series A financing co-led by Regeneron Ventures and Cure Ventures, and with participation by Invus Group.
Press Release
Representation of GV Management Company as lead in PeopleOne Health’s $32.3M Series B Financing.
Press Releasse
Representation of GV Management Company, as lead, and a16z Bio + in Santa Ana Bio’s $125M Series B Financing. Other investors included TPG, Access Biotechnology, and RTW.
Press Release
NextPoint Therapeutics raises $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint subsequently raises $42.5M in an extension to its Series B led by Catalio Capital Management, bringing the total raised to $122.5M. Additional investors in the round include MPM BioImpact, Invus, Sixty Degree Capital, Binney Street Capital, and Arkin Bio-Capital.
Website
Claris Bio closes latest venture round to bring total financing to roughly $60 million, accelerating its late-stage clinical development of a novel therapeutic agent for neurotrophic keratopathy. Investors include Novo Holdings A/S, RA Capital, Mass General Brigham Ventures, and Janus Henderson Investors
Press Release
Representation of GV, as lead, ARCH Venture Partners and DCVC in Chroma Medicine’s $135M Series B Financing
Press Release
Equity investments in multiple portfolio companies, including Hibercell
Website
Series A-3 preferred equity financing to continue advancing Epalex’s two clinical-stage development programs
Website
Vizgen raises Series C equity funding led by Blue Water Life Science Advisors, LLC, ARCH Venture Fund X, L.P. and other existing investors
Press Release
Vernal Biosciences raises $21M Series A equity funding led by Dynamk Life Sciences Fund, L.P., Charles River Laboratories, Inc. and Ampersand 2020 Limited Partnership
Press Release
Artax Biopharma raises Series B-4 round of equity funding led by Advent Life Sciences Fund II LP, Advent Life Sciences LLP, Columbus Life Science Fund II, FCR, Hiyuli Ventures Limited, Belinda A. Termeer, and other existing investors, plus new investors including Sound Bioventures Fund I AB and and Eli Lilly
Press Release
Dianthus raises $100 million Series A financing led by 5AM Ventures, Fidelity Management & Research Company, Avidity Partners, Venrock, Fairmount Funds, Tellus BioVentures and other investors
Press Release
Summation Bio raises Series A equity funding led by RA Capital Healthcare Fund, L.P., RA Capital NEXUS Fund, L.P., RA Capital NEXUS Fund III, L.P., Blackwell Partners LLC and other existing investors
Counsel to Aliada in completing its Series Seed financing, with investment from Johnson & Johnson Innovation, RA Capital, OrbiMed and Sanofi Ventures
Website
Vizgen raises Series B equity funding from Northpond Ventures LP, ARCH Venture Fund X, L.P., Novalis LifeSciences LLC, Tao Capital Management, Pura Vida Investments and other current investors
Press Release
Senior Administrative Assistant and Associate Corporate Paralegal
